NTUS - NTUS STOCK NEWS

Natus Medical Incorporated (NASDAQ: NTUS) has announced that it will release its third quarter 2021 financial results on November 4, after market close. A conference call is scheduled for November 5 at 8:00 a.m. ET to discuss the results and answer questions. Interested parties can access the call at 1-844-634-1441 domestically or 1-508-637-5658 internationally. A telephone replay will be available for 48 hours post-call, and the conference will also be streamed live online at Natus’s investor relations webpage.

Natus Medical (NASDAQ:NTUS) announced a significant achievement by securing a 5-year contract for its Patient Monitoring and Capital Equipment to be included in the United States government healthcare system's electronic catalog (ECAT). This contract, pre-vetted by the Defense Logistics Agency, enhances purchasing access for the Department of Defense and Veterans Affairs to a diverse range of Natus products, including neurodiagnostic and audiology equipment. The contract may extend for an additional five years, offering a streamlined transaction process to support military patients.

Natus Medical has appointed two new members, Bryant M. Moore and Eric J. Guerin, to its Board of Directors, expanding the board to eight members. Moore brings extensive experience from Abbott Laboratories and Medtronic, while Guerin has a strong financial background as CFO of CDK Global and experience with major medical device companies. The company aims to drive growth through innovation and acquisition strategies.

Natus Medical reported Q2 2021 revenue of $116.0 million, a 37% increase year-over-year. GAAP net income was $3.5 million ($0.10 per diluted share), recovering from a loss of $8.9 million in Q2 2020. Non-GAAP EPS increased to $0.29 from a loss of $0.13. Gross margin improved to 57.3%, up from 47.8% a year ago. The company anticipates Q3 revenues between $113.0 million and $117.0 million and raised full-year revenue guidance to $468.0 million - $475.0 million. Concerns remain over supply chain delays impacting future performance.

Natus Medical (NASDAQ:NTUS) has successfully completed its first clinical case using the newly launched XactTrode™ family of platinum subdural electrodes, aimed at epilepsy surgical monitoring. These electrodes are designed for temporary use (<30 days) to capture and stimulate electrical signals on the brain's surface. CEO Jonathan Kennedy expressed satisfaction with their performance and compatibility with Natus’ Quantum system, enhancing operational efficiency for healthcare teams. The XactTrodes are now available to enhance surgical options for patients with central nervous system disorders.

Natus Medical (NASDAQ: NTUS) will announce its Q2 2021 financial results on August 5, 2021, post-market close. A conference call for discussion will take place on August 6, 2021, at 8:00 a.m. ET. Interested parties can join by phone or via the company's website. This report highlights their ongoing commitment to providing solutions for central nervous and sensory system disorders.

Natus Medical Incorporated (NASDAQ:NTUS) announced the retirement of Dr. Barbara Paul as Chairperson of the Board effective June 30, 2021, after five years of service. Joshua Levine, an independent director since 2018, has been appointed as the new Chairperson. CEO Jonathan Kennedy praised Dr. Paul for her instrumental role in the company's transformation and acknowledged her contributions in guiding Natus. Dr. Paul's retirement was described as amicable, with no disagreements reported with the company or its management.

Natus Medical reported Q1 2021 revenue of $114.9 million, a 5% increase from Q1 2020. GAAP EPS stood at $0.07, recovering from a loss of $0.11 in the same quarter last year. Non-GAAP EPS rose to $0.16 compared to $0.04 in Q1 2020. The company achieved a GAAP gross margin of 57.9%. Looking ahead, Natus forecasts Q2 revenue between $112 million and $116 million and full-year revenue between $463.5 million and $473.5 million. The CEO expressed optimism about revenue recovery in 2021 and highlighted strong interest in new product launches.

Natus Medical Incorporated (NASDAQ: NTUS) announced its participation in the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021. During the event, CEO Jonathan Kennedy and CFO Drew Davies will present from 3:00 p.m. to 3:40 p.m. Eastern Time, followed by one-on-one meetings with institutional investors. Interested investors can schedule meetings through Needham representatives. The presentation will be available live and archived for 90 days on Natus’ Investor Relations website.